| Matthew Ryer Kelly, MD | |
|
300 1st Ave, Charlestown, MA 02129-3109 | |
| (617) 952-5000 | |
| Not Available |
| Full Name | Matthew Ryer Kelly |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 8 Years |
| Location | 300 1st Ave, Charlestown, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720432701 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Shore Medical Center - | Salem, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Shore Physicians Group Inc | 3577467224 | 488 |
News Archive
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.
Consumers experiencing relationship problems are more likely to prefer aesthetic experiences that reflect their negative mood, according to a new study in the Journal of Consumer Research.
Rhode Island is the fifteenth state to have the Interstate Compact for Medical Licensure introduced in its Legislature, with the introduction of HB 5571 by Representatives Joseph M. McNamara, Joseph J. Solomon, Jr., Michael A. Morin, David A. Coughlin, Jr., and Mia A. Ackerman and S. 423 by Senators Christopher Scott Ottiano, Joshua Miller, Donna Nesselbush, and Adam Satchell.
RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.
Cone Health today announced a dramatic reduction in healthcare-acquired infection (HAIs) rates after implementing an infection prevention program which includes Xenex room disinfection systems.
› Verified 5 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.
Consumers experiencing relationship problems are more likely to prefer aesthetic experiences that reflect their negative mood, according to a new study in the Journal of Consumer Research.
Rhode Island is the fifteenth state to have the Interstate Compact for Medical Licensure introduced in its Legislature, with the introduction of HB 5571 by Representatives Joseph M. McNamara, Joseph J. Solomon, Jr., Michael A. Morin, David A. Coughlin, Jr., and Mia A. Ackerman and S. 423 by Senators Christopher Scott Ottiano, Joshua Miller, Donna Nesselbush, and Adam Satchell.
RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.
Cone Health today announced a dramatic reduction in healthcare-acquired infection (HAIs) rates after implementing an infection prevention program which includes Xenex room disinfection systems.
› Verified 5 days ago
| Entity Name | North Shore Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588606123 PECOS PAC ID: 3577467224 Enrollment ID: O20050429000668 |
News Archive
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.
Consumers experiencing relationship problems are more likely to prefer aesthetic experiences that reflect their negative mood, according to a new study in the Journal of Consumer Research.
Rhode Island is the fifteenth state to have the Interstate Compact for Medical Licensure introduced in its Legislature, with the introduction of HB 5571 by Representatives Joseph M. McNamara, Joseph J. Solomon, Jr., Michael A. Morin, David A. Coughlin, Jr., and Mia A. Ackerman and S. 423 by Senators Christopher Scott Ottiano, Joshua Miller, Donna Nesselbush, and Adam Satchell.
RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.
Cone Health today announced a dramatic reduction in healthcare-acquired infection (HAIs) rates after implementing an infection prevention program which includes Xenex room disinfection systems.
› Verified 5 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.
Consumers experiencing relationship problems are more likely to prefer aesthetic experiences that reflect their negative mood, according to a new study in the Journal of Consumer Research.
Rhode Island is the fifteenth state to have the Interstate Compact for Medical Licensure introduced in its Legislature, with the introduction of HB 5571 by Representatives Joseph M. McNamara, Joseph J. Solomon, Jr., Michael A. Morin, David A. Coughlin, Jr., and Mia A. Ackerman and S. 423 by Senators Christopher Scott Ottiano, Joshua Miller, Donna Nesselbush, and Adam Satchell.
RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.
Cone Health today announced a dramatic reduction in healthcare-acquired infection (HAIs) rates after implementing an infection prevention program which includes Xenex room disinfection systems.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Ryer Kelly, MD 35 Lomasney Way Apt 2812, Boston, MA 02114-1520 Ph: () - | Matthew Ryer Kelly, MD 300 1st Ave, Charlestown, MA 02129-3109 Ph: (617) 952-5000 |
News Archive
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.
Consumers experiencing relationship problems are more likely to prefer aesthetic experiences that reflect their negative mood, according to a new study in the Journal of Consumer Research.
Rhode Island is the fifteenth state to have the Interstate Compact for Medical Licensure introduced in its Legislature, with the introduction of HB 5571 by Representatives Joseph M. McNamara, Joseph J. Solomon, Jr., Michael A. Morin, David A. Coughlin, Jr., and Mia A. Ackerman and S. 423 by Senators Christopher Scott Ottiano, Joshua Miller, Donna Nesselbush, and Adam Satchell.
RegeneRx Biopharmaceuticals, Inc. today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3 clinical trial for the orphan disorder, neurotrophic keratopathy (NK), and a 2b/3 dose-response, confirmatory trial for dry eye syndrome (DES) in the U.S. Both trials will be testing ReGenTree's preservative-free eye drops, RGN-259/GBT201, this year.
Cone Health today announced a dramatic reduction in healthcare-acquired infection (HAIs) rates after implementing an infection prevention program which includes Xenex room disinfection systems.
› Verified 5 days ago
Dr. Priyanca Shah, DO Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 300 1st Ave, Charlestown, MA 02129 Phone: 302-384-5120 Fax: 215-955-2311 | |
Dr. Nevena Zubcevik, DO Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 300 1st Ave, Charlestown, MA 02129 Phone: 617-952-6220 Fax: 617-952-6220 | |
Dayna Yorks, DO Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 300 1st Ave, Charlestown, MA 02129 Phone: 312-238-1000 | |
Ginger Polich, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 300 1st Ave, Charlestown, MA 02129 Phone: 617-952-5000 | |
David Michael Robinson, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 300 1st Ave, Charlestown, MA 02129 Phone: 248-842-4062 | |
Zhi Min Ng, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 42 8th St, 5517, Charlestown, MA 02129 Phone: 857-452-7234 | |
Razvan Turcu, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 300 1st Ave, Charlestown, MA 02129 Phone: 616-283-4088 |